| 货号 | 规格 | 价格 | 上海 | 北京 | 珠海 | 重庆 | 武汉 | 购买数量 |
|---|---|---|---|---|---|---|---|---|
S88832-5mg |
≥98% | ￥770.00 |
货期：3-5天 | - | - | - | - |
|
S88832-10mg |
≥98% | ￥1330.00 |
货期：3-5天 | - | - | - | - |
|
S88832-25mg |
≥98% | ￥2750.00 |
货期：3-5天 | - | - | - | - |
|
S88832-50mg |
≥98% | ￥4100.00 |
货期：3-5天 | - | - | - | - |
|
| 产品描述： | ON1231320 is a highly specific polo like kinase 2 (PLK2) inhibitor with an IC50 of 0.31 µM. ON1231320 blocks tumor cell cycle progression in the G2/M phase in mitosis, causing apoptotic cell death. ON1231320, an arylsulfonyl pyrido-pyrimidinone, has antitumor activity | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 靶点： | PLK2:0.31 μM (IC50);PLK1:>10 μM (IC50);PLK3:>10 μM (IC50);PLK4:>10 μM (IC50);Apoptosis; PLK | ||||||||||||||||||||
| 体内研究： | ON1231320 (Compound 7ao; 75 mg/kg; IP; alternate days (Q2D) for 20 days) results in significant inhibition of tumor growth. Animal Model: 6-8 week old NCR nu/nu female mice with MDAMB-231 triple negative breast cancer cells Dosage: 75 mg/kg Administration: IP; alternate days (Q2D) for 20 days Result: Resulted in significant inhibition of tumor growth (86.5%) | ||||||||||||||||||||
| 参考文献： | 1. M V Ramana Reddy, et al. Discovery of 2-(1H-indol-5-ylamino)-6-(2,4-difluorophenylsulfonyl)-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one (7ao) as a potent selective inhibitor of Polo like kinase 2 (PLK2). Bioorg Med Chem. 2016 Feb 15;24(4):521-44. 2. Shashidhar S. Jatiani, et al. Abstract 643: Targeting cancer with a selective ATP-mimetic inhibitor of polo like kinase-2. | ||||||||||||||||||||
| 溶解性： | Soluble in DMSO | ||||||||||||||||||||
| 保存条件： | 2-8℃ | ||||||||||||||||||||
| 配置溶液浓度参考： |
|
||||||||||||||||||||
| 注意： | 部分产品我司仅能提供部分信息，我司不保证所提供信息的权威性，仅供客户参考交流研究之用。 |
上海工商
沪公网安备 31011702002021号
危险品化学品经营许可证（不带存储）
营业执照(三证合一)
北京